ENOS antibody (AA 1156-1183)
Quick Overview for ENOS antibody (AA 1156-1183) (ABIN5536665)
Target
See all ENOS (NOS3) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 1156-1183
-
Purification
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
Immunogen
- This eNos antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1156-1183 amino acids from human eNos.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
-
For WB starting dilution is: 1:1000
For FACS starting dilution is: 1:10~50
For IF starting dilution is: 1:10~50 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.39 mg/mL
-
Buffer
- Supplied in PBS with 0.09 % (W/V) sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
-
-
- ENOS (NOS3) (Nitric Oxide Synthase 3 (Endothelial Cell) (NOS3))
-
Alternative Name
- eNos
-
Background
- Nitric oxide is a reactive free radical which acts as a biologic mediator in several processes, including neurotransmission and antimicrobial and antitumoral activities. Nitric oxide is synthesized from L-arginine by nitric oxide synthases. Variations in this gene are associated with susceptibility to coronary spasm. Multiple transcript variants encoding different isoforms have been found for this gene.
-
Molecular Weight
- 133 kDa
-
Gene ID
- 4846
-
UniProt
- P29474
-
Pathways
- ACE Inhibitor Pathway, Regulation of Systemic Arterial Blood Pressure by Hormones, Cellular Response to Molecule of Bacterial Origin, Myometrial Relaxation and Contraction, Signaling Events mediated by VEGFR1 and VEGFR2, Thromboxane A2 Receptor Signaling, VEGFR1 Specific Signals, VEGF Signaling
Target
-